2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action

Journal of Medicinal Chemistry

Volumn 41, Issue 23, 1998, Pages 4615-4622

  Earl, Richard A ^a,b   Zaczek, Robert ^a   Teleha, Christopher A ^a   Fisher, Barbara N ^a   Maciag, Carla M ^a   Marynowski, Maria E ^a   Logue, Andrew R ^a   Tam, S William ^a,b   Tinker, William J ^a   Huang, Shiew Mei ^a   Chorvat, Robert J ^a  

^a DUPONT COMPANY   (United States)

^b NitroMed Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,10 BIS(2 FLUORO 4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 2 FLUORO 4 PYRIDINYLMETHYL DERIVATIVE; ACETYLCHOLINE; LINOPIRDINE; LINOPIRINE DERIVATIVE; NOOTROPIC AGENT; UNCLASSIFIED DRUG;

ACETYLCHOLINE BRAIN LEVEL; ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; HIPPOCAMPUS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; ANTHRACENES; DRUG EVALUATION, PRECLINICAL; HIPPOCAMPUS; INDOLES; MALE; MICRODIALYSIS; NOOTROPIC AGENTS; PYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15444350005     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9803424     Document Type: Article

References (59)

1. Bondi, M. W.; Salmon, D. P.; Butters, N. M. Neuropsychological features of memory disorders. In Alzheimer's Disease; Terry, R. D., Katzman, R., Bick, K. L., Eds.; Raven Press: New York, 1993; pp 41-64.
2. Selkoe, D. J. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 1994, 489-518.
3. Yankner, B. A. Mechanisms of Neuronal Degeneration in Alzheimer's Disease. Neuron 1996, 16, 921-932.
4. Goedert, M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 1993, 16, 460-465.
5. Cochran, F. R.; Vitek, M. P. Neuroinflammatory mechanisms in Alzheimer's disease opportunities of drug discoveries. Exp. Opin. Invest. Drugs 1996, 5, 449-455.
6. McGeer, P. L.; McGeer, E. G. Immune mechanisms in neurodegenerative disorders. Drugs Today 1996, 32, 149-158.
7. Rogers, J.; Cooper, N. R.; Webster, S.; Schultz, J.; McGeer, P. L.; Styren, S. D.; Civin, W. H.; Brachove, L.; Bradt, B.; Ward, P.; Liebergerg, I. Complement activation by beta-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10016-10020.
8. Bartus, R. T.; Dean, R. L., III; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-417.
9. 2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985, 228, 1115-1117.
10. Sugaya, K.; Giacobini, E.; Chiappinelli, V. A. Nicotinic acetylcholine receptor subtytpes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res. 1990, 27, 349-359.
11. Whitehouse, P. J.; Kellar, K. J. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders. J Neural Transm. Suppl. 1987, 24, 175-182.
12. 1 muscarinic receptors to G-ptroteins in Alzheimer's disease. Alz. Dis. Assoc. Disord. 1991, 5, 163-172.
13. DeFeudis, F. V. Central cholinergic systems, cholinergic drugs and Alzheimer's disease - an overview. Drugs Today 1988, 24, 473-490.
14. Iverson, L. L. The cholinergic hypothesis of dementia. Trends Pharmacol. Sci. 1986, 44-45.
15. Perry, E. K. The cholinergic hypothesis-ten years on. Br. Med. Bull. 1986, 42, 63-69.
16. Coyle, J. T.; Price, D. L.; DeLong, M. R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983, 219, 1184-1190.
17. Whitehouse, P. J.; Price, D. L.; Struble, R. G.; Clark, A. W.; Coyle, J. T.; DeLong, M. R. Alzheimer's Disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215, 1237-1239.
18. El-Defrawy, S. R.; Coloma, F.; Jhamandas, K.; Boegman, R. J.; Beninger, R. J.; Wisching, B. A. Functional and neurochemical cortical cholinergic impairment following neurotoxic lesions of the nucleus basalis magnocellularis in the rat. Neurobiol. Aging 1985, 6, 325-330.
19. Hepler, D. J.; Wenk, G. L.; Cribbs, B. L.; Olton, D. S.; Coyle, J. T. Memory impairments following basal forebrain lesions. Brain Res. 1985, 346, 8-14.
20. Watson, M.; Vickroy, T. W.; Fibiger, H. C.; Roeske, W. R.; Yamamura, H. I. Effects of bilateral ibotenate-induced lesions of the nucleus basalis magnocellularis upon selective cholinergic biochemical markers in the rat anterior cerebral cortex. Brain Res. 1985, 346, 387-391.
21. Bartus, R. T. Evidence for a direct cholinergic involvement in the scopolamine induced amnesia in monkeys effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol. Biochem. Behav. 1978, 9, 833-836.
22. Caulfield, M. P.; Fortune, D. H.; Roberts, P. M.; Stubley, J. K. Intracerebroventricular hemicholinium-3 (HC-3) impairs learning of a passive aviodance task in mice. Br. J. Pharmacol. 1981, 74, 865.
23. Knapp, M. J.; et al. A 30-week randomized controlled trial of high dose tacrine in patients with alzheimer's disease. JAMA 1994, 271, 985-991.
24. Rogers, S. L.; Doody, R.; Mohs, R.; Friedhoff, L. T. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial. Neurology 1996, 46 (Suppl.), A217.
25. Rogers, S. Clinical profile of donepezil (E2020). 5th International Conference on Alzheimer's Disease and Related Disorders, 1996.
26. Earl, R. A.; Myers, M. J.; Johnson, A. L.; Scribner, R. M.; Wuonola, M. A.; Boswell, G. A.; Wilkerson, W. W.; Nickolson, V. J.; Tam, S. W.; Brittelli, D. R.; Chorvat, R. J.; Zaczek, R.; Cook, L.; Wang, C.; Zhang, X.; Lan, R.; Mi, B.; Wenting, H. Acetylcholine-releasing agents as cognition enhancers. Structure-activity relationships of pyridinyl pendant groups on selected core structures. Bioorg. Med. Chem. Lett. 1992, 2, 851-854.
27. Wilkerson, W. W.; Kergaye, A. A.; Tam, S. W. 3-Substituted, 3-(4-pyridinylmethyl)-1,3-dihydro-1-phenyl-2H-indol-2-ones as acetylcholine release enhancers: Synthesis and SAR. J. Med. Chem. 1993, 36, 2899-2907.
28. Boyd, N. D. Two distinct kinetic phases of desensitization of acetylcholine receptors of clonal rat PC 12 cells. J. Physiol. 1987, 389, 45-68.
29. Davis, R. E.; Doyle, P. D.; Carroll, R. T.; Emmerling, M. R.; Jaen, J. C. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering? Arzneim.-Forsch. / Drug Res. 1995, 45, 425-431.
30. Miller, S.; Mahoney, J.; Jann, M. Therapeutic frontiers in Alzheimer's disease. Pharmacotherapy 1992, 12.
31. Cook, L.; Nickolson, V. J.; Steinfels, G. F.; Rohrbach, K. W.; DeNoble, V. J. Cognition enhancement by the acetylcholine releaser DuP 996. Drug Dev. Res. 1990, 19, 301-314.
32. Zaczek, R.; Saydoff, J. Depolarization activated releasers of transmitters as therapeutics for dementia: Preclinical characterization of linopirdine (DuP 996). Curr. Opin. Invest. Drugs 1993, 2, 1097-1104.
33. Scrip report on DuP 996. Scrip 1992, No. 1775, 25.
34. Rakestraw, D. C.; Bilski, D. A.; Lam, G. N. Determination of linopirdine and its N-oxide metabolites in rat plasma by liquid chromatography. J. Pharm. Biomed. Anal. 1994, 12, 1055-1061.
35. Pieniaszek, H. J., Jr.; Fiske, W. D.; Saxton, T. D.; Kim, Y. S.; Garner, D. M.; Xilinas, M.; Martz, R. Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers. J. Clin. Pharmacol. 1995, 35, 22-30.
36. Hansch, C. W.; Bjorkroth, J. P.; Leo, A. Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 1987, 76, 663-687.
37. Gorrod, J. W.; Damani, L. A. The effect of various potential inhibitors, activators and inducers on the N-oxidation of 3-substituted pyridines in vitro. Xenobiotica 1979, 9, 219-226.
38. a. J. Am. Chem. Soc. 1974, 96, 3314-3316), the rate of oxidation of the 2-fluoropyridyl analogues by cytochrome P-450 should be reduced.
39. a. J. Am. Chem. Soc. 1974, 96, 3314-3316), the rate of oxidation of the 2-fluoropyridyl analogues by cytochrome P-450 should be reduced.
40. a. J. Am. Chem. Soc. 1974, 96, 3314-3316), the rate of oxidation of the 2-fluoropyridyl analogues by cytochrome P-450 should be reduced.
41. The N-oxide of 2-fluoropyridine has been generated by chemical oxidation of 2-fluoropyridine with trifluoroperacetic acid (Sarantakis, D.; Sutherland, J. K.; Tortorella, C.; Tortorella, V. 2-Fluoropyridine N-oxide and its reactions with amino acid derivatives. J. Chem. Soc. C 1968, 72-73). This 2-fluoropyridine N-oxide was shown to be a highly reactive intermediate that readily undergoes nucleophilic attack by amino acid derivatives. However, we were unable to oxidize the 2-fluoropyridine group in our molecules under a variety of conditions (e.g., m-CPBA, hydrogen peroxide (30%)/AcOH, urea-hydrogen peroxide/phthalic anhydride, urea-hydrogen peroxide/trifluoroacetic acid/sulfuric acid).
42. Stolle, R. Phenyloxindole. Chem. Ber. 1914, 47, 2120-2122.
43. Mlochowski, J.; Szulc, Z. Reactions of azafluorenones with hydrazine. Pol. J. Chem. 1983, 57, 33-39.
44. DuPriest, M. T.; Schmidt, C. L.; Kuzmich, D.; Williams, S. B. A facile synthesis of 7-halo-5H-indeno[1,2-b]pyridines and -pyridin-5-ones. J. Org. Chem. 1986, 51, 2021-2023.
45. Cheng, C. Y.; Chen, H. C.; Wu, S. C. Facile 3-alkylation of oxindoles under phase-transfer conditions - a modified synthesis of 3,3-dipyridylmethyl-1-phenyl-2-indolinone, an acetylcholine-release enhancer. Chung-hua Yao Hsueh Tsa Chih 1990, 42, 337-340.
46. Pierce, M. E.; Huhn, G. F.; Jensen, J. H.; Sigvardson, K. W.; Islam, Q.; Xing, Y. On the mechanism of the reduction of 1-phenyl-3-(4-pyridinylmethylene)-2-oxindole with sodium borohydride in methanol. J. Heterocycl. Chem. 1994, 31, 17-23.
47. Bryant, W. M., III; Huhn, G. F.; Jensen, J. H.; Pierce, M. E.; Stammbach, C. A large scale preparation of the cognitive enhancer linopirdine. Synth. Commun. 1993, 23, 1617-1625.
48. Kloc, K.; Mlochowski, J.; Szulc, Z. Synthesis of azafluorenones. J. Prakt. Chem. 1977, 319, 959-967.
49. Nickolson, V. J.; Tam, S. W.; Myers, M. J.; Cook, L. DuP 996 (3,3-bis(4-pyrindinylmethyl)-1-phenylindolin-2-one) enhances the stimulus-induced release of acetylcholine from rat brain in vitro and in vivo. Drug Dev. Res. 1990, 19, 285-300.
50. Aiken, S. P.; Lampe, B. J.; Murphy, P. A.; Brown, B. S. Reduction of spike-frequency adaptation and blockade of M-current in in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br. J. Pharmacol. 1995, 115, 1163-1168. Aiken, S. P.; Zaczek, R.; Brown, B. S. Pharmacology of the Neurotransmitter Release Enhancer Linopirdine (DuP 996) and Insights into Its Mechanism of Action. Adv. Pharmacol. 1996, 35, 349-384.
51. Aiken, S. P.; Lampe, B. J.; Murphy, P. A.; Brown, B. S. Reduction of spike-frequency adaptation and blockade of M-current in in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br. J. Pharmacol. 1995, 115, 1163-1168. Aiken, S. P.; Zaczek, R.; Brown, B. S. Pharmacology of the Neurotransmitter Release Enhancer Linopirdine (DuP 996) and Insights into Its Mechanism of Action. Adv. Pharmacol. 1996, 35, 349-384.
52. Brown, D. M-currents: an uppdate. Trends Neurosci. 1988, 11, 294-299.
53. Damsma, G.; Westerink, B. H. C.; deBoer, P.; de Vries, J. B.; Horn, A. S. Basal acetylcholine release in freely moving rats by on-line trans-striatal dialysis: Pharmacological aspects. Life Sci. 1988, 43, 1161-1168.
54. Hallak, M.; Giacobini, E. Physostigmine, tacrine and metrifonate: The effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989, 28, 199-206.
55. Potter, P. E.; Meek, J. L.; Neff, N. H. Acetylcholine and choline in neuronal tissue measured by HPLC with electrochemical detection. J. Neurochem. 1983, 41, 188-194.
56. 55 correlate well with those obtained by other groups: Smith, T. M.; Ramirez, A. D.; Jasys, V. J.; Volkmann, R. A.; Schaeffer, T. L.; Wilkinson, L. O. Effect of subchronic administration of DuP 996 on in vitro potassium stimulated acetylcholine release. Soc. Neurosci. Abstr. 1994, 20, 254.9.
57. Pieniaszek, H. J., Jr.; Garner, D. M.; Klingerman, C. A.; Kornhauser, D. M. Pharmacokinetics, Safety and Tolerance of DMP-543, a Potential Cognitive Enhancer, in Young and Elderly Male Subjects After Single Oral Doses. J. Clin. Pharmacol. 1997, 37, 867.
58. Zaczek, R.; Chorvat, R. J.; Saye, J. A.; Pierdomenico, M. E.; Maciag, C. M.; Logue, A. R.; Fisher, B. N.; Rominger, D. H.; Earl, R. A. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone (XE991) and 10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone (XR543): Comparison to linopirdine. J. Pharmacol. Exp. Ther. 1998, 285, 724-730.
59. Unpublished results.